GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chemomab Therapeutics Ltd (NAS:CMMB) » Definitions » Shares Outstanding (EOP)

Chemomab Therapeutics (Chemomab Therapeutics) Shares Outstanding (EOP) : 14.22 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chemomab Therapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Chemomab Therapeutics's shares outstanding for the quarter that ended in Mar. 2024 was 14.22 Mil.

Chemomab Therapeutics's quarterly shares outstanding increased from Dec. 2023 (14.20 Mil) to Mar. 2024 (14.22 Mil). It means Chemomab Therapeutics issued new shares from Dec. 2023 to Mar. 2024 .

Chemomab Therapeutics's annual shares outstanding increased from Dec. 2022 (11.05 Mil) to Dec. 2023 (14.20 Mil). It means Chemomab Therapeutics issued new shares from Dec. 2022 to Dec. 2023 .


Chemomab Therapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Chemomab Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemomab Therapeutics Shares Outstanding (EOP) Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
11.00 11.40 11.05 14.20

Chemomab Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.05 11.05 11.82 14.20 14.22

Competitive Comparison of Chemomab Therapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Chemomab Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemomab Therapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Chemomab Therapeutics's Shares Outstanding (EOP) falls into.



Chemomab Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Chemomab Therapeutics  (NAS:CMMB) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Chemomab Therapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Chemomab Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemomab Therapeutics (Chemomab Therapeutics) Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Tel Aviv, ISR, 6158002
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Executives
Orbimed Israel Biofund Gp Limited Partnership 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
George Adi Mor director, 10 percent owner, officer: Chief Executive Officer 15 KAFRISIN ST., TEL AVIV L3 6901658
Neil Harris Cohen director C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139
Matthew Bejosa Frankel officer: Chief Medical Officer 672 PROSPECT AVE., PRINCETON NJ 08540
Jill M. Quigley director TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Joel Michael Maryles director 5 ATZMON ST., HASHMONAIM L3 7312700
Donald Marvin officer: Executive VP, CFO & COO 2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104
Dale R Pfost director, officer: Chief Executive Officer ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Nissim Darvish director C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Peter Thiel 10 percent owner 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Sigal Fatal officer: Chief Financial Officer 16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716
Arnon Aharon officer: Chief Medical Officer 12 YAVNE ST., TEL AVIV L3 6579116
Alan Charles Moses director C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Stephen P Squinto director C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Israel Gp Ltd. 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629

Chemomab Therapeutics (Chemomab Therapeutics) Headlines

From GuruFocus